GHRP-2

Appetite Stimulation

GHRP-2 has been shown to significantly boost food intake in healthy adult men, mimicking the orexigenic effects of ghrelin (Laferrere et al., 2005). This effect extends to obese subjects, who also respond to the appetite-stimulating properties of GHRP-2 (Laferrere et al., 2006). Reliable appetite stimulation in the setting of chronic disease, cachexia, and post-surgical recovery could significantly improve long-term patient outcomes.

Cardioprotection

Research in fetal heart cell cultures shows that GHRP-2 and its analogues (GHRP-1, GHRP-6) protect heart cells by reducing apoptosis (Muccioli et al., 2000). This is particularly relevant following myocardial infarction, when cardiomyocytes are prone to programmed cell death due to ischemia. Studies with the related peptide hexarelin have identified specific cardiac receptors for growth hormone secretagogues, opening pathways for novel cardiovascular drug development (Bodart et al., 1999).

Immune System Enhancement

GHRP-2 stimulates the thymus, promoting T cell maturation and increasing both the number and diversity of T cells produced. Since thymic function declines with age, contributing to inadequate tissue repair, lost immunity, and increased susceptibility to infections and cancer, GHRP-2's ability to rejuvenate the thymus represents a significant potential application in aging-related immune decline (Taub et al., 2010).

Sleep Quality

GHRP-2 increases the duration of stage 3 and stage 4 sleep by approximately 50% each, increases REM sleep by roughly 20%, and reduces deviation from normal sleep patterns by up to one-third. These improvements translate to better cognitive function, blood pressure regulation, healing, and energy levels (Copinschi et al., 1997).

Pain Perception

GHRP-2 has demonstrated direct effects on pain perception through selective opioid receptor agonism. The peptide binds primarily to opioid receptors responsible for pain relief and sedation, raising the possibility of developing selective opioid agonists that could mitigate respiratory depression and addiction risks associated with traditional opioids (Zeng et al., 2014).

Muscle Preservation and Growth

Research in yaks demonstrates that GHRP-2 can overcome natural growth plateaus caused by food deprivation, disease, and adverse conditions by boosting muscle growth through increased protein deposition and decreased protein degradation (Hu et al., 2016). The most significant finding is that GHRP-2 reduces muscle atrophy by inactivating atrogin-1 and MuRF1, key regulators of the muscle degradation pathway (Yamamoto et al., 2008). By activating growth hormone and IGF-1, GHRP-2 encourages lean body mass development even in adverse conditions (Phung et al., 2000).

Ongoing & Future Research

Active and recent clinical investigations involving GHRP-2 and closely related ghrelin receptor agonists include:

• NCT00091585: Study of ghrelin and growth hormone secretagogues in GH-deficient subjects, examining diagnostic utility of the GHRP-2 stimulation test
• NCT00512356: Evaluation of ghrelin and GHRP-2 effects on appetite, food intake, and energy expenditure in healthy volunteers and obese subjects
• NCT01444703: Investigation of growth hormone secretagogue receptor agonists in cancer-related cachexia and appetite stimulation
• NCT00093613: Assessment of ghrelin and ghrelin mimetics on body composition and metabolic parameters in HIV-associated wasting

Broader ghrelin receptor agonist research continues in cachexia (cancer and COPD), sarcopenia of aging, wound healing acceleration, and functional GH deficiency diagnostics. The pralmorelin provocation test continues to gain adoption as a front-line diagnostic for GH deficiency in endocrinology practice.

Comparison to Related Compounds

GHRP-2 occupies a middle ground among growth hormone secretagogues. Compared to GHRP-6, it is more selective for GH release with less appetite stimulation and reduced cortisol/prolactin elevation at equivalent doses (Bowers et al., 1991). Unlike hexarelin, GHRP-2 does not bind the CD36 scavenger receptor, meaning it lacks the direct cardioprotective signaling that hexarelin provides. Ipamorelin is the most selective GHRP, producing virtually no cortisol or prolactin changes, but GHRP-2 produces a larger GH pulse magnitude. MK-677 (ibutamoren) is the only oral non-peptide ghrelin mimetic, offering convenience but with a much longer half-life that produces sustained rather than pulsatile GH elevation (Moulin et al., 2007).